Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
NCT05084859 · Biosplice Therapeutics, Inc. · PHASE1 · terminated · last registry update 2024-08-09 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was terminated due business reasons by Sponsor.” | – | Registry record, Biosplice Therapeutics, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CYP17A1 in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
No results, stops or Phase 3 starts on the same target in that window.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision